Results for "Beam Therapeutics"

Roivant Sciences presented at the Cantor conference, highlighting momentum in its pipeline following positive data from mosliciguat trials.

Prime Medicine (PRME) announced a positive resolution to its arbitration proceedings with Beam Therapeutics.

This report examines whether several companies, including Beam Therapeutics, MongoDB, Visa, and Waste Management, are currently considered good stock investments.

AbCellera (ABCL) is highlighted as one of the stocks with the potential to increase its value tenfold over the next five years, according to market analysts.

Beam Therapeutics announced its GAAP EPS at $2.33 and reported revenue of $114.1 million, providing an update on its financial performance.

H.C. Wainwright has reiterated its 'Buy' rating on Beam Therapeutics (BEAM) following the FDA's expedited approval of BEAM-302.

Beam Therapeutics has published interim clinical results for its BEAM-302 gene therapy candidate, demonstrating sustained efficacy and safety profiles over an 18-month treatment period for alpha-1 antitrypsin deficiency.

Prime Medicine's stock gained after the company announced it had won an arbitration case against Beam Therapeutics, resolving a dispute between the two firms.

Financial analyst Jim Cramer characterized Beam Therapeutics as a "speculative situation," indicating a high-risk, high-reward investment.

Beam Therapeutics is set to advance its gene-editing drug into pivotal development stages, marking a significant step in its therapeutic pipeline.

An analyst expresses a bullish sentiment on Beam Therapeutics (BEAM) due to the promising trajectory of its drug programs.

Bank of America Securities has reiterated its 'Buy' rating for Beam Therapeutics (BEAM), signaling continued confidence in the biotechnology company's stock.

Several companies, including Root, Adient, TaskUs, and Maximus, have released their earnings call transcripts or summaries for the first or second quarter of 2026. These reports provide financial updates and insights into their recent performance.

The CEO of Beam Therapeutics sold over 30,000 shares of the company, a move that has prompted analysis regarding its potential implications for investors.

Several financial firms have issued new ratings, price targets, or coverage initiations for biotech and pharmaceutical companies including Beam Therapeutics, Krystal Biotech, 4D Molecular Therapeutics, BioMarin Pharmaceutical, Vertex Pharmaceuticals, CRISPR Therapeutics AG, Regeneron Pharmaceuticals, and UniQure.

Here are some basic technical metrics that every investor should be aware of. They can be used as a check on our fundamental analysis.